Isofol Medical AB (publ) (STO:ISOFOL)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.693
+0.025 (3.82%)
At close: Mar 6, 2026
-57.77%
Market Cap 194.67M
Revenue (ttm) n/a
Net Income (ttm) -54.17M
Shares Out 281.11M
EPS (ttm) -0.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 898,949
Average Volume 3,428,018
Open 0.695
Previous Close 0.667
Day's Range 0.668 - 0.701
52-Week Range 0.552 - 2.440
Beta 0.88
RSI 51.97
Earnings Date Feb 18, 2026

About Isofol Medical AB

Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 6
Stock Exchange Nasdaq Stockholm
Ticker Symbol ISOFOL
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.